ATE508744T1 - 5-ä3-(4-benzyloxyphenylthio)-fur-2-ylü- imidazolidin-2, 4-dion und analoga als hemmer der makrophagenelastase - Google Patents

5-ä3-(4-benzyloxyphenylthio)-fur-2-ylü- imidazolidin-2, 4-dion und analoga als hemmer der makrophagenelastase

Info

Publication number: ATE508744T1
Authority: AT; Austria
Prior art keywords: benzyloxyphenylthio; fur; dione; ylü; analogas
Prior art date: 2004-08-19

Application number

AT05786673T

Other languages

English (en)

Inventor

Fude Yang

Original Assignee

Quest Pharmaceutical Services

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-19

Filing date

2005-08-17

Publication date

2011-05-15

2005-08-17 Application filed by Quest Pharmaceutical Services filed Critical Quest Pharmaceutical Services

2011-05-15 Application granted granted Critical

2011-05-15 Publication of ATE508744T1 publication Critical patent/ATE508744T1/de

Links

108030001712 Macrophage elastases Proteins 0.000 title abstract 2
102100027998 Macrophage metalloelastase Human genes 0.000 title abstract 2
239000003602 elastase inhibitor Substances 0.000 title 1
ZUOUZWHAINARGI-UHFFFAOYSA-N 5-[3-(4-phenylmethoxyphenyl)sulfanylfuran-2-yl]imidazolidine-2,4-dione Chemical compound O=C1NC(=O)NC1C1=C(SC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C=CO1 ZUOUZWHAINARGI-UHFFFAOYSA-N 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT05786673T 2004-08-19 2005-08-17 5-ä3-(4-benzyloxyphenylthio)-fur-2-ylü- imidazolidin-2, 4-dion und analoga als hemmer der makrophagenelastase ATE508744T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US60273604P	2004-08-19	2004-08-19
PCT/US2005/029259 WO2006023562A2 (en)	2004-08-19	2005-08-17	5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase

Publications (1)

Publication Number	Publication Date
ATE508744T1 true ATE508744T1 (de)	2011-05-15

Family

ID=35968136

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05786673T ATE508744T1 (de)	2004-08-19	2005-08-17	5-ä3-(4-benzyloxyphenylthio)-fur-2-ylü- imidazolidin-2, 4-dion und analoga als hemmer der makrophagenelastase

Country Status (16)

Country	Link
US (1)	US7179831B2 (de)
EP (1)	EP1789036B1 (de)
JP (1)	JP5042833B2 (de)
KR (1)	KR101197325B1 (de)
CN (1)	CN101014338B (de)
AT (1)	ATE508744T1 (de)
AU (1)	AU2005277432B2 (de)
BR (1)	BRPI0514470B8 (de)
CA (1)	CA2577430C (de)
DK (1)	DK1789036T3 (de)
ES (1)	ES2364068T3 (de)
MX (1)	MX2007001940A (de)
NZ (1)	NZ553258A (de)
RU (1)	RU2391339C2 (de)
SI (1)	SI1789036T1 (de)
WO (1)	WO2006023562A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2636990A1 (en) *	2006-01-13	2007-07-26	Battelle Memorial Institute	Animal model for assessing copd-related diseases
EP2907512A1 (de)	2014-02-14	2015-08-19	Commissariat A L'energie Atomique Et Aux Energies Alternatives	Hemmer von MMP-12 als antivirale Wirkstoffe
ES2910833T3 (es) *	2016-08-19	2022-05-13	Foresee Pharmaceuticals Co Ltd	Composición farmacéutica y procedimientos de usos
US10532102B2 (en)	2016-08-19	2020-01-14	Foresee Pharmaceuticals Co., Ltd.	Pharmaceutical composition and methods of uses
CN109803961B (zh) *	2016-09-23	2021-03-23	科研制药株式会社	(r)-5-(3,4-二氟苯基)-5-[(3-甲基-2-氧代吡啶-1(2h)-基)甲基]咪唑烷-2,4-二酮的制造方法及用于该制造的中间体
SG11202011318QA (en) *	2018-05-15	2020-12-30	Foresee Pharmaceuticals Usa Inc	Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
DK4058437T3 (da) *	2019-11-14	2025-01-20	Foresee Pharmaceuticals Usa Inc	Matrix-metalloproteinase-(MMP)-inhibitorer og fremgangsmåder til anvendelse heraf
KR20240019265A (ko) *	2021-06-08	2024-02-14	포시 파마슈티컬스 컴퍼니 리미티드	Mmp-12 억제제의 안전한 투여
RU2766551C1 (ru) *	2021-07-19	2022-03-15	Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ)	5-(4-хлорфенил)-3-((4-хлорфенил)амино)-5-(фенилтио)фуран-2(5н)-он, обладающий противомикробной активностью

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1817700A (en)	1998-12-31	2000-07-24	Aventis Pharmaceuticals Inc.	1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6352976B1 (en)	1998-12-31	2002-03-05	Aventis Pharmaceuticals Inc.	Selective inhibitors of MMP-12
RU2150469C1 (ru) *	1999-06-01	2000-06-10	Уфимский государственный нефтяной технический университет	Способ получения 2-(фурил-2)-1,3-имидазолидинов
AU4882101A (en)	2000-04-28	2001-11-12	Shionogi & Co., Ltd.	Mmp-12 inhibitors
SE0100903D0 (sv)	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
ATE445400T1 (de)	2001-05-25	2009-10-15	Bristol Myers Squibb Co	Hydantion-derivate als hemmer von matrix- metalloproteinasen
EP1394159A1 (de)	2002-08-13	2004-03-03	Warner-Lambert Company LLC	Neue Thiophen-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
SE0202539D0 (sv) *	2002-08-27	2002-08-27	Astrazeneca Ab	Compounds
GB0219896D0 (en)	2002-08-27	2002-10-02	Bayer Ag	Dihydropyridine derivatives
WO2004033632A2 (en) *	2002-10-04	2004-04-22	Bristol-Myers Squibb Company	Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US7132432B2 (en) *	2003-06-05	2006-11-07	Bristol-Myers Squibb Company	Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)

2005
- 2005-08-17 ES ES05786673T patent/ES2364068T3/es not_active Expired - Lifetime
- 2005-08-17 BR BRPI0514470A patent/BRPI0514470B8/pt not_active IP Right Cessation
- 2005-08-17 EP EP05786673A patent/EP1789036B1/de not_active Expired - Lifetime
- 2005-08-17 NZ NZ553258A patent/NZ553258A/en not_active IP Right Cessation
- 2005-08-17 MX MX2007001940A patent/MX2007001940A/es active IP Right Grant
- 2005-08-17 WO PCT/US2005/029259 patent/WO2006023562A2/en not_active Ceased
- 2005-08-17 CA CA2577430A patent/CA2577430C/en not_active Expired - Fee Related
- 2005-08-17 RU RU2007105822/04A patent/RU2391339C2/ru not_active IP Right Cessation
- 2005-08-17 AU AU2005277432A patent/AU2005277432B2/en not_active Ceased
- 2005-08-17 SI SI200531283T patent/SI1789036T1/sl unknown
- 2005-08-17 US US11/205,954 patent/US7179831B2/en not_active Expired - Lifetime
- 2005-08-17 JP JP2007527975A patent/JP5042833B2/ja not_active Expired - Fee Related
- 2005-08-17 AT AT05786673T patent/ATE508744T1/de not_active IP Right Cessation
- 2005-08-17 CN CN2005800285556A patent/CN101014338B/zh not_active Expired - Fee Related
- 2005-08-17 KR KR1020077006294A patent/KR101197325B1/ko not_active Expired - Fee Related
- 2005-08-17 DK DK05786673.3T patent/DK1789036T3/da active

Also Published As

Publication number	Publication date
JP2008510701A (ja)	2008-04-10
NZ553258A (en)	2011-02-25
RU2007105822A (ru)	2008-09-27
CA2577430C (en)	2010-12-07
EP1789036A4 (de)	2008-08-27
MX2007001940A (es)	2007-07-24
US20060041000A1 (en)	2006-02-23
BRPI0514470B1 (pt)	2021-01-05
BRPI0514470A (pt)	2008-06-10
KR101197325B1 (ko)	2012-11-05
KR20070045330A (ko)	2007-05-02
WO2006023562A3 (en)	2006-04-20
WO2006023562A2 (en)	2006-03-02
RU2391339C2 (ru)	2010-06-10
AU2005277432A1 (en)	2006-03-02
AU2005277432B2 (en)	2011-11-24
SI1789036T1 (sl)	2011-09-30
CN101014338A (zh)	2007-08-08
US7179831B2 (en)	2007-02-20
HK1107774A1 (en)	2008-04-18
BRPI0514470B8 (pt)	2021-07-20
DK1789036T3 (da)	2011-06-27
CN101014338B (zh)	2010-06-16
EP1789036A2 (de)	2007-05-30
EP1789036B1 (de)	2011-05-11
CA2577430A1 (en)	2006-03-02
ES2364068T3 (es)	2011-08-24
JP5042833B2 (ja)	2012-10-03
WO2006023562B1 (en)	2006-06-22

Legal Events

Date	Code	Title	Description
2011-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
FI20030213A0 (fi)	2003-02-12	Toimintamoodien valinta elektronisessa laitteessa
ATE467413T1 (de)	2010-05-15	Oxindolderivate als antikrebsmittel
EP1796709A4 (de)	2009-10-28	Analoga von shk-toxin und ihre verwendung als selektive inhibitoren von kv1.3-kaliumkanälen
DE502005011241D1 (de)	2011-05-26	Indazolderivate als inhibitoren der hormon-sensitiven lipase
ATE447404T1 (de)	2009-11-15	Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
EA200801381A1 (ru)	2009-02-27	Производные пиримидина
ATE517896T1 (de)	2011-08-15	P38-kinase-inhibitoren
ATE449605T1 (de)	2009-12-15	N3-alkylierte benzimidazol-derivate als mek- hemmer
EA201001359A1 (ru)	2011-04-29	Гетероциклические соединения в качестве ингибиторов cxcr2
EP1622569A4 (de)	2008-08-27	Aza-spiro-alkan-derivate als hemmer von metallproteasen
ATE416171T1 (de)	2008-12-15	2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
DE602005025733D1 (de)	2011-02-17	Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
DE602006008945D1 (de)	2009-10-15	Isochinolinderivate als inhibitoren von rho-kinase
DE60305061D1 (de)	2006-06-08	2-pyridonderivate als inhibitoren von neutrophiler elastase
DE602005013923D1 (de)	2009-05-28	Derivate von piperidinylalkylcarbamaten, herstellungsverfahren davon und verwendung derselben als faah-enzym-inhibitoren
DE602005009255D1 (de)	2008-10-02	Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
EP1789036A4 (de)	2008-08-27	5-¦3-(4-benzyloxyphenylthio)-fur-2-yl -imidazolidin-2, 4-dion und analoga als hemmer der makrophagenelastase
DE60313292D1 (de)	2007-05-31	Oxa- und thiadiazole und ihre verwendung als metalloproteinase-inhibitoren
EA200801145A1 (ru)	2008-10-30	Спироциклические производные хиназолина в качестве ингибиторов pde7
EA200801366A1 (ru)	2008-10-30	Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
ATE417849T1 (de)	2009-01-15	Pyrazoloä4,3-düpyrimidine
ATE490959T1 (de)	2010-12-15	Heterocyclische nichtimidazolverbindungen als modulatoren des histamin-h3-rezeptors
ATE542796T1 (de)	2012-02-15	N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
DK1637141T3 (da)	2012-02-27	Stabiliseret proteasesammensætning omfattende en serinprotease, morpholinderivater og reversible inhibitorer af serinproteasen
ATE329913T1 (de)	2006-07-15	Oxazole als mglur1 verstärker